Rezdiffra vs Viberzi
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Rezdiffra | US Viberzi | |
|---|---|---|
| Generic name | resmetirom | eluxadoline |
| Drug class | Thyroid Hormone Receptor-Beta Agonist | Mu-Opioid Receptor Agonist |
| Treats | Metabolic dysfunction-associated steatohepatitis (MASH) | Irritable bowel syndrome with diarrhea |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | Madrigal Pharmaceuticals | AbbVie |
| Year approved | 2024 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Diarrhea, Nausea, Itching, Gallbladder problems | Constipation, Nausea, Abdominal pain, Risk of pancreatitis |
Rezdiffra
Frequently asked questions
Is Rezdiffra or Viberzi better?
Neither is universally "better." Rezdiffra (resmetirom) and Viberzi (eluxadoline) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rezdiffra and Viberzi?
Rezdiffra is a Thyroid Hormone Receptor-Beta Agonist made by Madrigal Pharmaceuticals, while Viberzi is a Mu-Opioid Receptor Agonist made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rezdiffra has the larger estimated TV advertising budget of the two.